Introduction
The number of patients suffering from neoplasm in Europe amounts to over 3 million people, while mortality reaches 1.7 million people a year. Neoplastic metastases to the skeletal system occur in 50% of oncologic patients. In 70% of cases they are connected The presence of activated osteoclasts, osteoblasts, inflammatory cells, and neoplastic cells is observed in metastatic focus. Multidirectional interactions can be noticed between these components.
The majority of neoplastic cells show an ability to produce and release numerous factors that promote osteoclast multiplication, differentiation, and activation.
Radiology tests
Metastatic lesions in the bone in the initial phase infiltrate bone marrow, then surround the bone and thus disturb the balance enhancing osteolytic or osteoblastic processes. Scintigraphic test with the use of 
PET
The first radiopharmaceutical used for imaging skeletal lesions was sodium fluoride ( 18 F-NaF), introduced in the sixties. In the seventies phosphonate labelled derivatives were introduced into scintigraphy [2] . Their sensitivity, diagnostic effectiveness, and cost appeared to be so attractive that studies with the use of 18 F-NaF became considerably limited. However, currently, due to PET-CT development, an increasing interest in this radiopharmaceutical can be observed [3] . The second frequently used radiopharmaceutical in bone metastases diagnostics is 18 FDG. In many cases the studies that use both tracers are complementary.
F-NaF
This radiopharmaceutical was first used by Blau et al. [4] in 1962. Considerably better PET resolution and 18 F-NaF pharmacokinetic properties make it a great tracer in evaluation of bone metastases [5] and lesions in the course of trauma and metabolic diseases. This radiopharmaceutical was registered by the FDA as a safe and effective drug in diagnostics of skeletal diseases.
The
18 F dose applied in diagnostic studies is less than 8.4 μg/kg. Therefore, no pharmacodynamic effect of the radiopharmaceutical is observed. Data on toxicity, genotoxicity, or cancerogenesis are not known as the preparation dose used in the study is trace and typically administered only once. No studies connected with the radiopharmaceutical effect on the foetus have been carried out.
However, the rules of patient radiology protection should be the same as in the case of other radioactive preparations.
No data on radiopharmaceutical content in breast milk of nursing mothers can be found. Thus, breastfeeding ought to be stopped. The safety of the 18 F-NaF effect on children has not been determined. Thus, the study on this group of patients can be conducted following a profound analysis of risks and benefits (similarly to other pharmaceuticals from this group, particularly the intense accumulation of The pharmacokinetics of 18 F-NaF were recently described by Modlin et al. [6] . Accumulation level of 18 F-NaF in the skeletal system depends most of all on blood flow. Almost all fluorides accumulate in bone tissue as early as during the first passing. Accumulation within bone marrow is scarce.
The accumulation mechanism of 18 F-NaF involves fast chemisorption on hydroxyapatite crystals. Next, they are exchanged with Tc-MDP, 18 F-NaF also accumulates in benign lesions, which is a limitation to the method in oncologic diagnostics.
Increased 18
F-NaF accumulation is observed in inflammations, past trauma, fibrous dysplasia, Paget's disease, hyperostosis frontalis, and myositis ossificans [5, 6] . Differentiation of these lesions with metastatic foci based on tracer uptake (SUV) is impossible, which considerably impedes test result interpretation. 18 F-NaF test is not applied in routine diagnostics of bone metastases due to limited availability and cost. Indications for 18 F-NaF test are as follows: high risk of tumour dissemination to bone despite normal or unclear 99m Tc-MDP scintigraphy picture and diagnosis of neoplastic disease with osteolytic bone metastases [7] [8] [9] . It is currently assumed that diagnosis of lung, mam- Bury et al. [11] compared the sensitivity and specificity of PET/CT test with 18 F-NaF and scintigraphy after 99m Tc-MDP administration in 110 patients. The sensitivity of both PET and classic scintigraphy amounted to 90%, while specificity was 98% and 61%, respectively.
Even-Sapir et al. [1] compared studies with the use of 99m Tc-MDP (WB, SPECT) as well as with the use of 99m Tc-MDP performed on 44 patients with prostatic cancer and high risk of bone metastases. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were as follows:
for WB -70%, 57%, 64% and 55%, respectively, for SPECT -92%,82%, 86%, and 90%, respectively, for PET -100%, 62%, 74%, and 100%, respectively, while in the case of PET/CT all the parameters amounted to 100%. 
F-FDG
18 F-FDG is the most commonly used tracer in diagnostics of neoplastic disease with the use of PET technique. Contrary to 18 F-NaF, this radiopharmaceutical is not bone specific. However, it should be emphasized that compared to other diagnostic methods, 18 F-FDG has a great property which allows for direct imaging of metastatic lesions (the radiopharmaceutical accumulates in neoplastic cells, while other methods allow determination of indirect signs of the disease).
18 F-FDG is transported to cells by transport protein present in the Glut cellular membrane. A considerably higher Glut 1 protein expression is observed in neoplastic cells. The protein transports glucose to the cell without insulin participation.
The process of phosphorylation takes place in the cell.
In normal bone marrow low glucose metabolism can be typically observed and thus accumulation of 18 F-FDG is also low. Increased glucose metabolism also occurs in early stage of metastasis, during bone marrow infiltrate before any visible reaction Review of bone tissue. Therefore, the foci diagnosed following 18 F-FDG administration might not be visible in CT and scintigraphy.
The sensitivity of 18 F-FDG PET in detecting bone metastases amounts to 62-100% while specificity amounts to 96-100% [1] . PET with 
Conclusions
Studies on the skeletal system with the use of PET/CT are used in clinical practice more and more often. In particular, the role of 
Values of this technique include:
-two-fold greater tracer accumulation in skeletal system compared with 99m Tc-MDP; -considerably quicker 18 F-NaF excretion from blood (due to lack of affinity to blood proteins); -high value of bone tissue/background coefficient; -shorter test duration; -easy patient preparation for the test; no limitations to diet of physical activity are required; -possibility of conducting the test regardless of glucose concentration in the blood.
